Eight stock picks to play one of the healthiest corners of the market

The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull market.

Market Watch • Dec 11, 2025

High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth

The Touchstone Mid Cap Growth Fund outperformed its benchmark, the Russell Midcap® Growth Index, for the quarter ended September 30, 2025. From a factor perspective, the Fund's overweight exposure to size was a relative tailwind to performance, offsetting a headwind from being underweight volatility. Consumer Discretionary was the largest source of relative gains.

Seeking Alpha • Dec 11, 2025

Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ

The Investment Committee give you their top stocks to watch for the second half.

CNBC Television • Dec 8, 2025

Ascendis: Q3 Results Validate The TransCon Platform

Ascendis Pharma has achieved operational profitability, driven by YORVIPATH's rapid adoption and strong Q3 2025 revenues of €213.6 million. ASND's robust cash position (€539 million) and self-sustaining business model eliminate near-term dilution risk and support continued pipeline investment. TransCon platform advances, including SKYTROFA label expansion and TransCon CNP, offer significant growth opportunities, with regulatory risk now mostly administrative.

Seeking Alpha • Dec 5, 2025

Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026

The U.S. Food & Drug Administration (FDA) on Tuesday extended review for Ascendis Pharma A/S‘ (NASDAQ: ASND) New Drug Application (NDA) for TransCon CNP (navepegritide) for children with achondroplasia.

Benzinga • Nov 28, 2025

US FDA extends review of Ascendis Pharma's therapy for children with dwarfism

The U.S. Food and Drug Administration on Tuesday extended its review of Ascendis Pharma's therapy for children with a rare genetic disorder that causes dwarfism, the company said.

Reuters • Nov 25, 2025

Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

–  Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) notified the Company that information submitted on November 5, 2025, related to the post-marketing requirement, in response to the FDA's ongoing review of the New Drug Application (NDA) for TransCon CNP (navepegritide) for children with achondroplasia, constituted a major amendment to the NDA. Accordingly, the FDA has extended the PDUFA target action date by three months to February 28, 2026.

GlobeNewsWire • Nov 25, 2025

Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics

COPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial of investigational once-weekly TransCon® CNP (navepegritide) in children with achondroplasia have been published in JAMA Pediatrics, a journal of the American Medical Association. In the publication, titled “Once-Weekly Navepegritide in Children with Achondroplasia: The ApproaCH Randomized Clinical Trial,” the authors report that treatment with TransCon CNP led to significantly higher annualized growth velocity (AGV) at Week 52 compared to placebo (primary endpoint), as well as improved lower-limb alignment and body proportionality and positive changes in health-related quality of life, with a safety and tolerability profile similar to placebo. The abstract can be accessed on the JAMA Pediatrics website.

GlobeNewsWire • Nov 17, 2025

Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Chad Fugere Jan Mikkelsen - President, CEO, Member of Executive Board & Executive Director Scott Smith - CFO, Executive VP & Member of Executive Board Jay Wu - Executive VP & President of Ascendis US Aimee Shu - Executive VP & Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Tazeen Ahmad - BofA Securities, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Yaron Werber - TD Cowen, Research Division Martin Auster - Raymond James & Associates, Inc., Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Yun Zhong - Wedbush Securities Inc., Research Division Charles Ndiaye - Stifel, Nicolaus & Company, Incorporated, Research Division Luca Issi - RBC Capital Markets, Research Division Maxwell Skor - Morgan Stanley, Research Division Yuxi Dong - Jefferies LLC, Research Division Presentation Operator Good day, and welcome to the Third Quarter 2025 Ascendis Pharma Earnings Conference Call. [Operator Instructions] I would now like to turn the call over to Chad Fugere, Vice President of Investor Relations at Ascendis Pharma.

Seeking Alpha • Nov 13, 2025

Ascendis Pharma Reports Third Quarter 2025 Financial Results

–   Q3 2025 revenue of €143.1 million for YORVIPATH ® and €50.7 million for SKYTROFA ®

GlobeNewsWire • Nov 12, 2025